Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
GALECTIN THERAPEUTICS INC (GALT) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/13/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update"
08/14/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update"
05/11/2018 8-K Quarterly results
Docs: "Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update"
11/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update"
08/18/2017 8-K/A Quarterly results
08/14/2017 8-K Quarterly results
Docs: "Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial"
05/15/2017 8-K Form 8-K - Current report
11/08/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update"
05/10/2016 8-K Quarterly results
Docs: "Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update"
11/12/2013 8-K Quarterly results
Docs: "Galectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 Financial Results"
08/14/2013 8-K Quarterly results
Docs: "Galectin Therapeutics Reports Second Quarter 2013 Financial Results"
11/09/2012 8-K Quarterly results
Docs: "Galectin Therapeutics Reports Third Quarter 2012 Financial Results"
08/10/2012 8-K Quarterly results
Docs: "Galectin Therapeutics Reports Second Quarter 2012 Financial Results"
05/11/2012 8-K Quarterly results
Docs: "Galectin Therapeutics Reports First Quarter 2012 Financial Results"
08/14/2009 8-K Quarterly results
Docs: "Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results"
05/15/2009 8-K Form 8-K -- Current report
11/07/2008 8-K Quarterly results
Docs: "Pro-Pharmaceuticals Reports Third Quarter Results"
08/08/2008 8-K Quarterly results
Docs: "Pro-Pharmaceuticals Reports Second Quarter Results"
05/20/2008 8-K Quarterly results
Docs: "PRO-PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS"
08/10/2007 8-K Quarterly results
Docs: "Results of Operations and Financial Condition",
"Pro-Pharmaceuticals Reports Second Quarter Results"
11/13/2006 8-K Quarterly results
Docs: "Item 2.02 Results of Operations and Financial Condition.",
"Pro-Pharmaceuticals Reports Third Quarter 2006 Results"
11/23/2004 8-K Quarterly results
Docs: "Pro-Pharmaceuticals Reports Third Quarter Results",
"Dr. David Platt Gratified with Arbitrator's Decision: Continues to Control Prosecution of Modified Pectin Patent Applications Patent Applications Relate to GCS-100, GlycoGenesys' Core Technology Decision Has No Bearing on Dr. Platt's Lawsuit Against GlycoGenesys or Their Counterclaims Against Dr. Platt & Pro-Pharmaceuticals Newton, MA, November 12, 2004 - David Platt, Ph.D., CEO & President of Pro-Pharmaceuticals, Inc. , today said he was gratified by the Arbitrator's decision to allow him to continue to control the prosecution of his patent applications that relate to the modified pectin technology that he developed and licensed to GlycoGenesys, Inc. in 1994. The Arbitrator ruled that Dr. Platt will continue to retain the power of attorney to control prosecution of his U.S. Patent Applica...",
"Pro-Pharmaceuticals “Sets the Record Straight” Regarding Misleading Statements Made by GlycoGenesys in News Releases Newton, MA, November 18, 2004 - Pro-Pharmaceuticals, Inc. , a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, is “Setting the Record Straight” regarding misleading statements made by GlycoGenesys, Inc. in two news releases issued on November 11. The news releases relate to an Arbitration decision between David Platt, Ph.D., President & CEO of Pro-Pharmaceuticals and GlycoGenesys, and pending Litigation between GlycoGenesys, Dr. Platt and Pro-Pharmaceuticals."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy